Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

Show other versions (1)

Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent...

Full description

Bibliographic Details
Main Authors: J Robert McCorkle, Justin W Gorski, Jinpeng Liu, McKayla B Riggs, Anthony B McDowell, Nan Lin, Chi Wang, Frederick R Ueland, Jill M Kolesar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0254205

Internet

https://doi.org/10.1371/journal.pone.0254205

Similar Items